PharmSol, since its inception in 2004, has been active in development and commercialization of various Finished Products and APIs.

Over the years, PharmSol, with its inhouse techno-commercial expertise in the areas of R&D, Manufacturing, Analytical and Business Development, has successfully developed and commercialized 25 APIs, 115(+) FDFs, facilitated 65(+) Tech Transfers and has also been involved in EU Registration of 70(+) Products leading to 350 MAs.

The Products include 18 on-patent pipeline generics, wherein PharmSol has the distinction of being first-to-file in EU. PharmSol offers a comprehensive list of Products spanning across various therapeutic categories and are available for our partners and customers through various customized business models:

50+

Licensing & Supply

350+

Tech Transfer

17

Co-developments

12

Contract Developments & Manufacturing

All the above business models are supported with IPR and Registration activities and hence, PharmSol guarantees end-to-end solution for successfully achieving the client’s objective.

The development pipeline of PharmSol is continually growing and updating. We solicit interest from customers across all geographies to be one of our partners in ongoing and future developments.

Additionally, PharmSol offers tailored market access services including Importation, Serialization, Batch Testing & Release, MA Holding, Marketing and Distribution.